VIJOICE (alpelisib) tablets

Alpelisib is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.

In the European Union, alpelisib is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)‑positive, human epidermal growth factor receptor 2 (HER2)‑negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy.

In April 2022, the indication for alpelisib was expanded in the US to include the treatment of severe manifestations of PIK3CA-related overgrowth spectrum (PROS) in those who require systemic therapy.

Common side effects include high blood sugar, kidney problems, diarrhea, rash, low blood cells, liver problems, pancreatitis, vomiting, and hair loss. It is an alpha-specific PI3K inhibitor. It was approved for medical use in the United States in May 2019.

How And Where To Buy alpelisib Tablets?

alpelisib Tablets can be ordered on request direct from Medvitaz Pharma Solutions if the drug has not been approved or is not available in your country. We help you to get genuine, affordable and assurance of delivery. To get best retail price/cost of alpelisib Tablets in India, Call 8750295029 or Email [email protected]. FDA approved drugs of Australia, Canada, EU, India, New Zealand, Singapore, Switzerland, Turkey & USA.